{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pigmentation+Disorders&page=2",
    "query": {
      "condition": "Pigmentation Disorders",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pigmentation+Disorders&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T19:43:31.965Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03941184",
      "title": "Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SCAD",
        "Addison Disease",
        "Ankylosing Spondylitis",
        "Antiphospholipid Antibody Syndrome",
        "Celiac Disease",
        "Crohn Disease",
        "Dermatomyositis",
        "Polymyositis",
        "Guillain-Barre Syndrome",
        "Hepatitis, Autoimmune",
        "Graves Disease",
        "Hashimoto Thyroiditis",
        "Multiple Sclerosis",
        "Myasthenia Gravis",
        "Pernicious Anemia",
        "Polymyalgia Rheumatica",
        "Primary Biliary Cirrhosis",
        "Psoriasis",
        "Rheumatoid Arthritis",
        "Systemic Sclerosis",
        "Sjögren Syndrome",
        "Systemic Lupus Erythematosus",
        "Takayasu Arteritis",
        "Type 1 Diabetes Mellitus",
        "Ulcerative Colitis",
        "Uveitis",
        "Vasculitis",
        "Vitiligo",
        "Raynaud"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 114,
      "start_date": "1995-01-01",
      "completion_date": "2020-11-10",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03941184"
    },
    {
      "nct_id": "NCT02809976",
      "title": "Topical Ruxolitinib for the Treatment of Vitiligo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vitiligo"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib 1.5% Phosphate Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-01",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02809976"
    },
    {
      "nct_id": "NCT05210582",
      "title": "A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Vitiligo"
      ],
      "interventions": [
        {
          "name": "Afamelanotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clinuvel, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2022-10-11",
      "completion_date": "2023-08",
      "has_results": false,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05210582"
    },
    {
      "nct_id": "NCT05692596",
      "title": "The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Pancreatic Cyst",
        "Chronic Pancreatitis",
        "Fatty Pancreas",
        "Genetic Pancreatic Cancer",
        "Genetic Pancreatitis",
        "BRCA Mutation",
        "Lynch Syndrome",
        "FAP",
        "Familial Atypical Multiple Mole-Melanoma",
        "PALB2 Gene Mutation",
        "Peutz-Jeghers Syndrome",
        "Ataxia Telangiectasia"
      ],
      "interventions": [
        {
          "name": "Data collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2022-10-06",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05692596"
    },
    {
      "nct_id": "NCT01735955",
      "title": "Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia (CML)",
        "Metastatic Gastrointestinal Stromal Tumors (GIST)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Receptor Tyrosine Kinase (KIT) Mutated Melanoma"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 57,
      "start_date": "2013-03-29",
      "completion_date": "2023-07-07",
      "has_results": true,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 2,
      "location_summary": "Albany, New York • Houston, Texas",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735955"
    },
    {
      "nct_id": "NCT04619589",
      "title": "Characterization of Dyschromic Hypertrophic Scar",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Burn Scar",
        "Hypertrophic Scar",
        "Hyperpigmentation",
        "Hypopigmented Scar"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-05-21",
      "completion_date": "2023-06-28",
      "has_results": false,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619589"
    },
    {
      "nct_id": "NCT02165631",
      "title": "The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension",
        "Pigment Dispersion Syndrome",
        "Pseudoexfoliation Glaucoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2014-08",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165631"
    },
    {
      "nct_id": "NCT01670162",
      "title": "On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age Related Macular Degeneration",
        "Pigment Epithelial Detachment"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tennessee Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-08",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2014-10-29",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Lexington, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670162"
    },
    {
      "nct_id": "NCT00001161",
      "title": "Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Aniridia",
        "Eye Abnormality",
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "1977-07",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001161"
    },
    {
      "nct_id": "NCT00814073",
      "title": "Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Indolent Systemic Mastocytosis"
      ],
      "interventions": [
        {
          "name": "Masitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 135,
      "start_date": "2008-12",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-07-23T19:43:31.965Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Houston, Texas",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00814073"
    }
  ]
}